

# Vladimir Makarov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1449929/publications.pdf>

Version: 2024-02-01

40  
papers

21,223  
citations

172386

29  
h-index

289141

40  
g-index

41  
all docs

41  
docs citations

41  
times ranked

27534  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	6.0	6,756
2	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2189-2199.	13.9	3,753
3	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016, 351, 1463-1469.	6.0	2,445
4	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	13.5	1,515
5	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015, 162, 974-986.	13.5	1,408
6	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <i>Nature</i> , 2017, 551, 512-516.	13.7	854
7	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	6.0	834
8	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. <i>Nature</i> , 2017, 551, 517-520.	13.7	532
9	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	6.0	395
10	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019, 25, 767-775.	15.2	282
11	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <i>Oncotarget</i> , 2016, 7, 10051-10063.	0.8	247
12	Integrated Genomic Analysis of H <sub>1</sub> Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. <i>Cancer Cell</i> , 2018, 34, 256-270.e5.	7.7	195
13	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 1715-1720.	15.2	194
14	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	7.7	179
15	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	3.2	153
16	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. <i>Clinical Cancer Research</i> , 2017, 23, 4429-4440.	3.2	142
17	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. <i>Nature Genetics</i> , 2018, 50, 62-72.	9.4	137
18	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 4276-4289.	3.9	134

#	ARTICLE	IF	CITATIONS
19	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. <i>Nature Genetics</i> , 2016, 48, 1327-1329.	9.4	115
20	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	5.7	114
21	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
22	An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. <i>Cell Reports</i> , 2017, 20, 1623-1640.	2.9	96
23	RIG-I activation is critical for responsiveness to checkpoint blockade. <i>Science Immunology</i> , 2019, 4, .	5.6	80
24	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <i>Nature Communications</i> , 2017, 8, 1197.	5.8	77
25	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 2859-2870.	3.2	75
26	Transcriptional diversity of long-term glioblastoma survivors. <i>Neuro-Oncology</i> , 2014, 16, 1186-1195.	0.6	69
27	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3168-3180.	3.2	67
28	Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. <i>Clinical Cancer Research</i> , 2018, 24, 963-971.	3.2	57
29	SCN4A pore mutation pathogenetically contributes to autosomal dominant essential tremor and may increase susceptibility to epilepsy. <i>Human Molecular Genetics</i> , 2015, 24, ddv410.	1.4	38
30	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	3.2	30
31	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. <i>Nature Genetics</i> , 2022, 54, 996-1012.	9.4	30
32	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	1.6	28
33	H3K9 methylation drives resistance to androgen receptor antagonist therapy in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114324119.	3.3	21
34	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
35	GIGYF2 mutation in late-onset Parkinson's disease with cognitive impairment. <i>Journal of Human Genetics</i> , 2015, 60, 637-640.	1.1	16
36	Genetics and immunology: reinvigorated. <i>Oncolmmunology</i> , 2015, 4, e1029705.	2.1	7

#	ARTICLE	IF	CITATIONS
37	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 1516-1525.	3.2	6
38	Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 382-394.	1.9	6
39	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. <i>Neoplasia</i> , 2022, 28, 100790.	2.3	5
40	Resource-efficient pooled sequencing expands translational impact in solid tumors. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2021, 19, 18-23.	0.1	1